Storia in 8 fonti

What's Going On With Eli Lilly Stock Tuesday? - Eli Lilly (NYSE:LLY)

Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.

Raccontata dabiopharmadive.comqz.comendpoints.newsstatnews.comcnbc.compharmaceutical-technology.comupi.combenzinga.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo3 h fa

What's Going On With Eli Lilly Stock Tuesday? - Eli Lilly (NYSE:LLY)

Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.

originale

cnbc.com9 h fa

Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.

Leggi questa versione → originale

biopharmadive.com21 h fa

Lilly dives into vaccine research with 3 biotech buyouts

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

Leggi questa versione → originale

upi.com6 h fa

Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - UPI.com

Eli Lilly announced Tuesday that it is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., in deals totaling nearly $4 billion.

Leggi questa versione → originale

endpoints.news10 h fa

Three vaccine biotechs to be bought by Lilly for up to $3.8B

Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious disease. The pharma is buying Curevo, LimmaTech Biologics and Vaccine Company.

Leggi questa versione → originale

pharmaceutical-technology.com9 h fa

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

Leggi questa versione → originale

Timeline cronologica

1. martedì 26 maggio 2026·biopharmadive.com
   

   Lilly dives into vaccine research with 3 biotech buyouts

   Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

2. martedì 26 maggio 2026·qz.com
   

   Eli Lilly acquires three vaccine developers for $3.8 billion

   The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs

3. martedì 26 maggio 2026·endpoints.news
   

   Three vaccine biotechs to be bought by Lilly for up to $3.8B

   Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious disease. The pharma is buying Curevo, LimmaTech…

4. martedì 26 maggio 2026·statnews.com
   

   Eli Lilly to buy three small vaccine developers

   Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.

5. martedì 26 maggio 2026·cnbc.com
   

   Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

   The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.

6. martedì 26 maggio 2026·pharmaceutical-technology.com
   

   Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology

   Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

7. martedì 26 maggio 2026·upi.com
   

   Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - UPI.com

   Eli Lilly announced Tuesday that it is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., in deals totaling nearly $4 billion.

8. martedì 26 maggio 2026·benzinga.com
   

   What's Going On With Eli Lilly Stock Tuesday? - Eli Lilly (NYSE:LLY)

   Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.